Patients navigate an ‘absolutely insane' maze to afford weight-loss drugs
'It's crazy,' she said of the ever-changing insurance landscape for weight-loss medications. 'It's absolutely insane to try to keep up with it all.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Abbott Laboratories (ABT): I Am Very Upset With Abbott,' Says Jim Cramer
We recently published . Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer recently discussed. Abbott Laboratories (NYSE:ABT) is a healthcare company. While it was one of Cramer's top stocks for most of this year, this show saw the CNBC TV host take a different tone. Abbott Laboratories (NYSE:ABT)'s shares fell by 8.5% in July after the firm's latest earnings results saw it warn about a massive $1 billion hit in 2025 from tariffs. Here's what Cramer said about the firm: 'I am very upset with Abbott. They're on tonight. I have supported the company for years and years. It's the diagnostic business. We'll have Robert Ford on tonight, it's not catastrophic because I like the company, long term. But, this is not, this was another thing that happened this morning that I found quite disturbing. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Previously, Cramer discussed Abbott Laboratories (NYSE:ABT)'s earnings before the release: 'Then one of my absolute favorite companies, medical device maker, Abbott Labs reports. And you know, I always like to tell you which companies tend to be misinterpreted in a negative way during the earnings season. Abbott's a textbook example. It bothers me, but there are always sellers who claim to be disappointed. So, if you don't own any Abbott, may I suggest that you wait to see the numbers, wait for the stock's opening, wait for the sellers to appear. Patience is a virtue with ABT.' While we acknowledge the potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade
Key Points Pfizer and Novo Nordisk have underperformed the market over the past year. But both should remain major players in important areas within the pharma industry. Investors could see the two drugmakers' shares beat the market over the next decade. 10 stocks we like better than Pfizer › Pharmaceutical giants Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) have lagged the market over the past year, although Pfizer's poor performance dates back much further. Though these companies have encountered challenges, there are good reasons to be bullish on their long-term prospects. Pfizer could become an even bigger player in the oncology market (the largest therapeutic area in the industry by sales) over the next decade, while Novo Nordisk will be a major player in diabetes and the fast-growing weight management space. Both could produce excellent results along the way. Here's the rundown. 1. Pfizer Pfizer's financial results haven't been great in recent years. To make matters worse, the company will face important patent cliffs by the end of the decade. One of them will be for Eliquis, an anticoagulant that is still one of its best-selling medicines. However, Pfizer has prepared for that eventuality. The company made several acquisitions and licensing deals that significantly boosted its pipeline, especially in oncology. Pfizer spent $43 billion to acquire Seagen, a smaller cancer specialist whose lineup and pipeline were impressive for a company of its size. With the financial and strategic backing of the larger company, it should yield even more key approvals in the field in the coming years. Pfizer also recently made an up-front payment of $1.25 billion to China-based 3SBio for the rights to SSGJ-707, an investigational bispecific antibody, a portion of the oncology market that's gaining traction these days. 3SBio will be eligible for commercial and regulatory milestone payments of up to $4.8 billion, not including royalties. These moves should eventually pay off for Pfizer and strengthen its position in oncology. The drugmaker plans to have eight blockbuster cancer medicines on the market by 2030, up from its current five, while doubling its reach from the current 1 million patients it serves. Of course, Pfizer isn't just a cancer play. The company's extensive pipeline should enable it to launch products in other areas and ultimately get back on track. While its shares have been lagging the market significantly, that could change in the next decade as financial results rebound thanks to its innovative efforts. Pfizer's shares look especially attractive when considering its valuation. Its forward price-to-earnings (P/E) ratio is 8.7, much lower than the healthcare sector's 15.8. From their current levels, Pfizer's shares could go on to generate excellent returns through 2035. 2. Novo Nordisk Novo Nordisk pioneered the market for weight management medicines. However, Eli Lilly seems to have taken the lead in that field, at least for now. Novo Nordisk has faced some clinical setbacks, leading to a poor performance over the trailing-12-month period. Can the company rebound and perform well in the next decade? In my view, it can, and the market may be significantly undervaluing its potential. Its sales of Wegovy, one of the top-selling anti-obesity medications, continue to grow rapidly. Novo Nordisk recently requested approval from the U.S. Food and Drug Administration for oral semaglutide (the active ingredient in Wegovy). That's good for patients who want a non-injected option, and helps counter Lilly's up-and-coming oral GLP-1 medicine, orforglipron. Elsewhere, Novo Nordisk recently started phase 3 studies for amycretin, a next-gen weight loss candidate. Amycretin is being investigated in both oral and subcutaneous formulations, and both are currently in late-stage clinical trials. The company also enhanced its pipeline through licensing deals, including one with United Biotechnology, a subsidiary of the China-based company United Laboratories International Holdings, for UBT251. This potential anti-obesity medicine mimics the actions of three gut hormones: GLP-1, GIP, and glucagon. The transaction cost Novo Nordisk an up-front payment of $200 million and up to $1.8 billion in milestone payments. Thanks to all these developments, Novo Nordisk should remain a leader in weight management in the next decade. Even though competition is mounting, no drugmaker not named Eli Lilly has a lineup or a pipeline as deep as Novo Nordisk's. Furthermore, the Denmark-based pharmaceutical leader will also continue to dominate the diabetes market, as it has done for decades. Novo Nordisk generates consistent revenue and earnings that typically grow faster than those of similarly-sized peers. Yet the stock's forward P/E is 16.7, which is slightly above the industry average. In my view, that's a bargain for a company that generates better-than-average results and has a deep pipeline in a fast-growing area -- not to mention two of the world's top 20 best-selling drugs, in Wegovy and Ozempic. For investors willing to stay the course, Novo Nordisk's future still looks incredibly bright. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Elevance Health, Inc. (ELV): I Won't Touch It With A 10 Foot Pole, Says Jim Cramer
We recently published . Elevance Health, Inc. (NYSE:ELV) is one of the stocks Jim Cramer recently discussed. Elevance Health, Inc. (NYSE:ELV) is one of the biggest healthcare benefits companies in America. Its shares have dipped by 24% year-to-date, primarily on the back of a 19% dip in July. Elevance Health, Inc. (NYSE:ELV)'s shares fell after the firm cut its profit forecast to $30 per share from an earlier $34.15 to $34.85 per share. Here's what Cramer said about the firm: 'They missed. I think we're finally at the point where people have said, these guys are all going to keep going down so don't worry about it. Don't sell. That stock is down much less than I thought it would be. I'm not, I mean that. Like these ones, have been, when they go down, they don't just go down nine. But this thing has been down for a while. I wouldn't touch these stocks with a ten-foot pole. They're just, this is happening before they even eviscerated Medicaid. I don't think people realize that the thing in that beautiful bill was a huge gift to accelerated depreciation, a huge gift for R&D. And just a house of pain for anything Medicaid.' A medical professional working at a computer, utilizing the company's digital solutions to improve care quality for consumers. GreensKeeper Asset Management mentioned Elevance Health, Inc. (NYSE:ELV) in its Q1 2025 investor letter. Here is what the firm said: 'Rounding out our top 5 performers in Q1 were Elevance Health, Inc. (NYSE:ELV) +17.9% and Intercontinental Exchange (ICE) + 15.8%. As mentioned in the last Scorecard, we believe the sell-off in ELV over the past year has been overdone, and the stock is trading at a significant discount to our estimate of its intrinsic value. The recent rebound reflects a partial correction of that mispricing. ICE continues to perform well as a significant portion of its earnings is driven by transaction volume on its exchanges and increasing demand for financial data, both of which generally increase when panic-induced volatility hits the markets.' While we acknowledge the potential of ELV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
